ATE146174T1 - Verfahren für die herstellung von toxane derivaten - Google Patents

Verfahren für die herstellung von toxane derivaten

Info

Publication number: ATE146174T1
Authority: AT; Austria
Prior art keywords: pct; vii; date; alkyl; alkenyl
Prior art date: 1992-10-05

Application number

AT93921982T

Other languages

English (en)

Inventor

Jean-Manuel Mas

Viviane Charriere B Massonneau

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-05

Filing date

1993-10-04

Publication date

1996-12-15

1993-10-04 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1996-12-15 Application granted granted Critical

1996-12-15 Publication of ATE146174T1 publication Critical patent/ATE146174T1/de

Links

238000000034 method Methods 0.000 title abstract 2
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 abstract 1
YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 abstract 1
OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 abstract 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
230000010933 acylation Effects 0.000 abstract 1
238000005917 acylation reaction Methods 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
150000001412 amines Chemical group 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
150000001602 bicycloalkyls Chemical group 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
230000008030 elimination Effects 0.000 abstract 1
238000003379 elimination reaction Methods 0.000 abstract 1
230000032050 esterification Effects 0.000 abstract 1
238000005886 esterification reaction Methods 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epoxy Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

AT93921982T 1992-10-05 1993-10-04 Verfahren für die herstellung von toxane derivaten ATE146174T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9211741A FR2696458B1 (fr)	1992-10-05	1992-10-05	Procédé de préparation de dérivés du taxane.

Publications (1)

Publication Number	Publication Date
ATE146174T1 true ATE146174T1 (de)	1996-12-15

Family

ID=9434119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93921982T ATE146174T1 (de)	1992-10-05	1993-10-04	Verfahren für die herstellung von toxane derivaten

Country Status (24)

Country	Link
US (3)	US5616739A (de)
EP (1)	EP0663906B1 (de)
JP (1)	JP3014760B2 (de)
KR (1)	KR100311198B1 (de)
AT (1)	ATE146174T1 (de)
AU (1)	AU689080B2 (de)
CA (1)	CA2146250C (de)
CZ (1)	CZ283261B6 (de)
DE (1)	DE69306591T2 (de)
DK (1)	DK0663906T3 (de)
ES (1)	ES2095081T3 (de)
FI (1)	FI109793B (de)
FR (1)	FR2696458B1 (de)
GR (1)	GR3021997T3 (de)
HU (1)	HU226412B1 (de)
MX (1)	MX9305766A (de)
NO (1)	NO309089B1 (de)
NZ (1)	NZ256445A (de)
PL (1)	PL182284B1 (de)
RU (1)	RU2116303C1 (de)
SK (1)	SK280627B6 (de)
TW (1)	TW419472B (de)
WO (1)	WO1994007877A1 (de)
ZA (1)	ZA937318B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2696464B1 (fr) *	1992-10-05	1994-11-10	Rhone Poulenc Rorer Sa	Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2697522B1 (fr) *	1992-10-30	1994-11-25	Rhone Poulenc Rorer Sa	Procédé de préparation de dérivés du taxane.
FR2698361B1 (fr) *	1992-11-20	1995-01-13	Rhone Poulenc Rorer Sa	Procédé de préparation d'un acide oxazolidine-1,3 carboxylique-5.
IL107950A (en)	1992-12-15	2001-04-30	Upjohn Co	7β, 8β - METHANO-TAXOLS, THEIR PREPARATION AND ANTINEOPLASTIC PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5973160A (en) *	1992-12-23	1999-10-26	Poss; Michael A.	Methods for the preparation of novel sidechain-bearing taxanes
ES2205663T3 (es) *	1993-06-11	2004-05-01	PHARMACIA & UPJOHN COMPANY	Uso antineoplasico de delta 6,7-taxoles y composiciones farmaceuticas que los contienen.
FR2706457B1 (fr) *	1993-06-16	1995-07-28	Rhone Poulenc Rorer Sa	Procédé de préparation d'un acide oxazolidinecarboxylique utile pour préparer des taxoïdes thérapeutiquement actifs.
US6005120A (en)	1993-07-20	1999-12-21	Florida State University	Tricyclic and tetracyclic taxanes
KR100354309B1 (ko) *	1993-11-12	2003-01-06	파마시아 앤드 업존 캄파니	피리미딘-티오알킬및알킬에테르화합물
IL127598A (en) *	1994-01-28	2003-04-10	Upjohn Co	Process for preparing isotaxol analogs
US5679807A (en) *	1995-01-30	1997-10-21	Hauser, Inc.	Preparation of taxol and docetaxel through primary amines
CA2170661A1 (en) *	1995-03-22	1996-09-23	John K. Thottathil	Novel methods for the preparation of taxanes using oaxzolidine intermediates
GB9512471D0 (en) *	1995-06-20	1995-08-23	Pharmacia Spa	Method for the preparation of taxol and its derivatives
US5688977A (en) *	1996-02-29	1997-11-18	Napro Biotherapeutics, Inc.	Method for docetaxel synthesis
ATE223889T1 (de) *	1996-05-08	2002-09-15	Upjohn Co	Oxazolidinester
US7288665B1 (en) *	1997-08-18	2007-10-30	Florida State University	Process for selective derivatization of taxanes
US6111144A (en)	1997-08-21	2000-08-29	Florida State University	Method for the synthesis of a taxane intermediate
WO1999032109A1 (en) *	1997-12-23	1999-07-01	Bristol-Myers Squibb Company	7-deoxy-6-nitrogen substituted paclitaxels
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CZ2003837A3 (cs) *	2000-09-22	2004-12-15	Bristol-Myers Squibb Company	Způsob pro snížení toxicity při kombinovaných chemoterapiích
US6891050B2 (en) *	2001-08-10	2005-05-10	Dabur India Limited	Process for the preparation of taxanes such as paclitaxel, docetaxel and structurally similar analogs
US6881852B2 (en) *	2002-02-05	2005-04-19	Dabur India Limited	Process of purification of paclitaxel and docetaxel
US7247738B2 (en) *	2002-05-07	2007-07-24	Dabur India Limited	Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids
US6900342B2 (en) *	2002-05-10	2005-05-31	Dabur India Limited	Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US7351542B2 (en)	2002-05-20	2008-04-01	The Regents Of The University Of California	Methods of modulating tubulin deacetylase activity
EP1530465B2 (de) *	2002-06-26	2015-12-16	MediGene AG	Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
US20040132991A1 (en) *	2002-10-09	2004-07-08	Phytogen Life Sciences Inc.	Novel taxanes and methods related to use and preparation thereof
US6838569B2 (en)	2002-12-16	2005-01-04	Dabur India Limited	Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
CA2525647A1 (en)	2003-05-16	2005-02-24	Intermune, Inc.	Synthetic chemokine receptor ligands and methods of use thereof
US7407973B2 (en) *	2003-10-24	2008-08-05	Intermune, Inc.	Use of pirfenidone in therapeutic regimens
US7202370B2 (en) *	2003-10-27	2007-04-10	Conor Medsystems, Inc.	Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III
US7597884B2 (en) *	2004-08-09	2009-10-06	Alios Biopharma, Inc.	Hyperglycosylated polypeptide variants and methods of use
WO2006020580A2 (en) *	2004-08-09	2006-02-23	Alios Biopharma Inc.	Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
EP1647552A1 (de) *	2004-10-08	2006-04-19	INDENA S.p.A.	Teilsynthese für die Herstellung von 10-deacetyl-n-debenzoyl-paclitaxel
US7446126B2 (en)	2004-10-08	2008-11-04	Indena S.P.A.	Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1712552A1 (de) *	2005-04-11	2006-10-18	INDENA S.p.A.	Teilsynthese für die Herstellung von 10-deacetyl-n-debenzoyl-paclitaxel
US8691780B2 (en) *	2005-02-17	2014-04-08	The Board Of Trustees Of The Leland Stanford Junior University	Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
BRPI0709075A2 (pt)	2006-03-20	2011-10-11	Medigene Ag	tratamento de cáncer de mama triplo receptor negativo
EP2001874A4 (de) *	2006-03-21	2010-04-07	Reddys Lab Ltd Dr	Docetaxel-polymorphe und entsprechende verfahren
ITMI20062479A1 (it) *	2006-12-21	2008-06-22	Indena Spa	Processo per la preparazione di secotassani
EP2296645B1 (de)	2008-05-22	2014-11-19	Galera Therapeutics, LLC	Antitumorale kombinationstherapie
KR101003822B1 (ko)	2008-06-20	2010-12-27	주식회사 셀트리온화학연구소	도세탁셀의 제조방법 및 도세탁셀의 제조를 위한 신규한중간체
EP2310507A4 (de)	2008-07-08	2013-03-20	David Gladstone Inst	Verfahren und zusammensetzungen zur angiogenesemodulierung
CN101735179B (zh) *	2008-11-19	2012-09-12	上海百灵医药科技有限公司	一种多烯紫杉醇的制备方法，其中间体及制备方法
EP2358693A4 (de) *	2008-11-20	2012-04-18	Reddys Lab Ltd Dr	Herstellung von docetaxel
PL388144A1 (pl)	2009-05-29	2010-12-06	Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością	Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
EP3539563A1 (de)	2012-07-19	2019-09-18	Redwood Bioscience, Inc.	Für cd22 spezifischer antikörper und verfahren zur verwendung davon
AU2013341711A1 (en)	2012-11-12	2015-05-21	Redwood Bioscience, Inc.	Compounds and methods for producing a conjugate
DK2956175T3 (da)	2013-02-15	2017-11-27	Univ California	Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
WO2014160185A2 (en)	2013-03-14	2014-10-02	The Board Of Trustees Of The Leland Stanford Junior University	Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN115504924A (zh)	2013-11-27	2022-12-23	雷德伍德生物科技股份有限公司	肼基-吡咯并化合物及用于生成缀合物的方法
HUE051255T2 (hu)	2014-02-19	2021-03-01	Aviv Therapeutics Inc	Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére
AR099812A1 (es)	2014-03-21	2016-08-17	Abbvie Inc	Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
US10654875B2 (en)	2015-11-12	2020-05-19	The Board Of Trustees Of The Leland Stanford Junior University	Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh)	2015-12-30	2022-04-11	杏國新藥股份有限公司	乳癌治療
EP3231421A1 (de)	2016-04-11	2017-10-18	Greenaltech, S.L.	Verwendungen eines carotenoids bei der behandlung oder prävention von durch stress verursachten störungen
JP2019515677A (ja)	2016-04-26	2019-06-13	アール．ピー．シェーラーテクノロジーズエルエルシー	抗体複合体ならびにそれを作製および使用する方法
CN109640961B (zh)	2016-06-01	2021-11-02	施维雅知识产权英国有限公司	聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法
WO2017214322A1 (en)	2016-06-08	2017-12-14	Abbvie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates
JP2019524651A (ja)	2016-06-08	2019-09-05	アッヴィ・インコーポレイテッド	抗ｃｄ９８抗体及び抗体薬物コンジュゲート
US20200147235A1 (en)	2016-06-08	2020-05-14	Abbvie Inc.	Anti-cd98 antibodies and antibody drug conjugates
MX2018015285A (es)	2016-06-08	2019-09-18	Abbvie Inc	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AU2017279550A1 (en)	2016-06-08	2019-01-03	Abbvie Inc.	Anti-B7-H3 antibodies and antibody drug conjugates
TWI852903B (zh)	2017-01-05	2024-08-21	杏國新藥股份有限公司	胰臟癌治療
JP7280827B2 (ja)	2017-01-18	2023-05-24	エクスマバイオテックコーポレイション	Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
EP3388082A1 (de)	2017-04-13	2018-10-17	Galera Labs, LLC	Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex
WO2018218004A1 (en)	2017-05-24	2018-11-29	The Board Of Regents Of The University Of Texas System	Linkers for antibody drug conjugates
CA3090129A1 (en)	2018-01-31	2019-08-08	Galera Labs, Llc	Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CA3096202A1 (en)	2018-04-06	2019-10-10	The Regents Of The University Of California	Methods of treating egfrviii expressing glioblastomas
CA3095757A1 (en)	2018-04-06	2019-10-10	The Regents Of The University Of California	Methods of treating glioblastomas
BR112020020930A2 (pt)	2018-04-11	2021-03-02	Ohio State Innovation Foundation	composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
CA3105879A1 (en)	2018-07-18	2020-01-23	Manzanita Pharmaceuticals, Inc.	Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
JP7716623B2 (ja)	2019-04-02	2025-08-01	ウィリアムロバートアラスーンリビングトラストデイテッドオーガスト 29, 2016	排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
WO2021155028A1 (en)	2020-01-29	2021-08-05	Kenjockety Biotechnology, Inc.	Anti-mdr1 antibodies and uses thereof
WO2021247426A1 (en)	2020-06-04	2021-12-09	Kenjockety Biotechnology, Inc.	Anti-abcg2 antibodies and uses thereof
CN116529267A (zh)	2020-06-04	2023-08-01	肯乔克蒂生物技术股份有限公司	Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
CA3193588A1 (en)	2020-09-02	2022-03-10	Kenjockety Biotechnology, Inc.	Anti-abcc1 antibodies and uses thereof
WO2022103603A1 (en)	2020-11-13	2022-05-19	Kenjockety Biotechnology, Inc.	Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
US12187810B2 (en)	2020-11-20	2025-01-07	R.P. Scherer Technologies, Llc	Glycoside dual-cleavage linkers for antibody-drug conjugates
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
US20250051471A1 (en)	2021-12-13	2025-02-13	William Robert Arathoon Living Trust Dated August 29, 2016	Anti-Abcb1 Antibodies
WO2023159220A1 (en)	2022-02-18	2023-08-24	Kenjockety Biotechnology, Inc.	Anti-cd47 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5175315A (en) *	1989-05-31	1992-12-29	Florida State University	Method for preparation of taxol using β-lactam
US5136060A (en) *	1989-11-14	1992-08-04	Florida State University	Method for preparation of taxol using an oxazinone
US5015744A (en) *	1989-11-14	1991-05-14	Florida State University	Method for preparation of taxol using an oxazinone
MX9102128A (es) *	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5319112A (en) *	1992-08-18	1994-06-07	Virgnia Tech Intellectual Properties, Inc.	Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol

1992
- 1992-10-05 FR FR9211741A patent/FR2696458B1/fr not_active Expired - Lifetime
1993
- 1993-09-21 MX MX9305766A patent/MX9305766A/es unknown
- 1993-10-01 ZA ZA937318A patent/ZA937318B/xx unknown
- 1993-10-02 TW TW082108117A patent/TW419472B/zh not_active IP Right Cessation
- 1993-10-04 ES ES93921982T patent/ES2095081T3/es not_active Expired - Lifetime
- 1993-10-04 PL PL93308241A patent/PL182284B1/pl unknown
- 1993-10-04 CA CA002146250A patent/CA2146250C/fr not_active Expired - Lifetime
- 1993-10-04 US US08/411,692 patent/US5616739A/en not_active Expired - Lifetime
- 1993-10-04 AT AT93921982T patent/ATE146174T1/de active
- 1993-10-04 CZ CZ95841A patent/CZ283261B6/cs not_active IP Right Cessation
- 1993-10-04 KR KR1019950701302A patent/KR100311198B1/ko not_active Expired - Lifetime
- 1993-10-04 RU RU95113717A patent/RU2116303C1/ru active
- 1993-10-04 HU HU9500971A patent/HU226412B1/hu unknown
- 1993-10-04 SK SK436-95A patent/SK280627B6/sk not_active IP Right Cessation
- 1993-10-04 EP EP93921982A patent/EP0663906B1/de not_active Expired - Lifetime
- 1993-10-04 WO PCT/FR1993/000967 patent/WO1994007877A1/fr not_active Ceased
- 1993-10-04 DK DK93921982.0T patent/DK0663906T3/da active
- 1993-10-04 NZ NZ256445A patent/NZ256445A/en not_active IP Right Cessation
- 1993-10-04 JP JP6508787A patent/JP3014760B2/ja not_active Expired - Lifetime
- 1993-10-04 AU AU51150/93A patent/AU689080B2/en not_active Expired
- 1993-10-04 DE DE69306591T patent/DE69306591T2/de not_active Expired - Lifetime
1995
- 1995-03-29 NO NO951201A patent/NO309089B1/no not_active IP Right Cessation
- 1995-04-04 FI FI951595A patent/FI109793B/fi not_active IP Right Cessation
1996
- 1996-10-31 US US08/742,101 patent/US5677462A/en not_active Expired - Lifetime
- 1996-12-12 GR GR960402201T patent/GR3021997T3/el unknown
1997
- 1997-08-08 US US08/908,806 patent/US5869680A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO951201D0 (no)	1995-03-29
US5869680A (en)	1999-02-09
SK43695A3 (en)	1995-08-09
JP3014760B2 (ja)	2000-02-28
DE69306591D1 (de)	1997-01-23
AU5115093A (en)	1994-04-26
GR3021997T3 (en)	1997-03-31
DE69306591T2 (de)	1997-04-17
AU689080B2 (en)	1998-03-26
ES2095081T3 (es)	1997-02-01
MX9305766A (es)	1995-01-31
HUT72679A (en)	1996-05-28
EP0663906B1 (de)	1996-12-11
KR950703546A (ko)	1995-09-20
EP0663906A1 (de)	1995-07-26
CZ84195A3 (en)	1995-09-13
CA2146250C (fr)	2003-03-11
FI951595L (fi)	1995-04-04
FI951595A0 (fi)	1995-04-04
RU95113717A (ru)	1996-12-27
WO1994007877A1 (fr)	1994-04-14
CA2146250A1 (fr)	1994-04-14
FR2696458B1 (fr)	1994-11-10
US5677462A (en)	1997-10-14
SK280627B6 (sk)	2000-05-16
FI109793B (fi)	2002-10-15
DK0663906T3 (da)	1996-12-30
ZA937318B (en)	1994-04-25
NO309089B1 (no)	2000-12-11
FR2696458A1 (fr)	1994-04-08
RU2116303C1 (ru)	1998-07-27
TW419472B (en)	2001-01-21
KR100311198B1 (ko)	2002-04-24
PL308241A1 (en)	1995-07-24
NZ256445A (en)	1997-01-29
NO951201L (no)	1995-03-29
JPH08501788A (ja)	1996-02-27
PL182284B1 (pl)	2001-12-31
CZ283261B6 (cs)	1998-02-18
US5616739A (en)	1997-04-01
HU226412B1 (en)	2008-11-28
HU9500971D0 (en)	1995-06-28

Publication	Publication Date	Title
DE69306591D1 (de)	1997-01-23	Verfahren für die herstellung von toxane derivaten
DE69308154D1 (de)	1997-03-27	Verfahren zur herstellung von taxan-derivaten
ATE147735T1 (de)	1997-02-15	Verfahren zur herstellung von taxan-derivaten
HU9500970D0 (en)	1995-06-28	Novel method of esterification of baccatine iii and 10-deacetylbaccatine iii